HRMY

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc. (HRMY) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.3) C (2.3) B (3.5) B (3.2) C+ (2.6) B- (3.0)
2026-11-05 B (3.3) B- (3.1) B (3.5) B (3.2) C+ (2.7) B- (3.1)
2026-10-29 B (3.3) B- (2.9) B (3.5) B (3.4) C+ (2.7) B- (3.1)
2026-10-22 B (3.3) B- (2.9) B (3.5) B (3.5) C+ (2.6) B (3.2)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe